Although my short talk was canceled after a fire alarm decided to make its own opening remarks, I still enjoyed the opportunity to share our work with colleagues and leadership at the Moffitt Symposium 2026. This year’s symposium featured over 270 posters!
I am excited to share our @NatureComms paper describing the structure of #LAG3 bound to MHC-II. This project was carried out by @SuperMQQ et al at @MoffittResearch and provides new insights into the mechanism by which LAG3 suppresses T cell activation. https://t.co/8HiBfWeYV7
New review from the Luca lab, where we cover new Notch technologies such as affinity-matured ligands, synthetic Notch receptors and transcriptional inhibitors of the Notch pathway.
https://t.co/ZLHCofHM2g
@TrendsinPharma
Our latest review in @TrendsinPharma! We cover recent Notch-based biotech with a focus on T cell therapy & synNotch. Things have really 'stepped up a Notch' (cringe) in the past few years. Great effort from @ElliotMedina31 @antfolk_daniel & David Perez
https://t.co/wEKmbOQy06
“It seemed absolutely crazy. The idea that an Iowa housewife, equipped with the cutting-edge medical tool known as Google Images, would make a medical discovery about a pro athlete who sees doctors and athletic trainers as part of her job?” https://t.co/iELohgpQHH
DeltaMAX, our engineered ultra-potent Notch-ligand got the cover of the January 2023 issue of Nature Chemical Biology @nchembio
DeltaMAX in green with the mutations in yellow, Notch in magenta/red
@DeividsGP postdoc work in the Luca lab, illustration by Eric Smith
My lab (@antfolk_daniel@srishti503@SuperMQQ and co.) curing cancer and saving the galaxy in their Men in Black costumes. Definitely the sharpest dressed I’ve seen this crew in awhile…
https://t.co/5xeY99ie9A
Out just now! My super talented colleague Qianqian Ming has just published the first structure of the immune checkpoint LAG3. This publication couldn’t be any more timely as the FDA just approved a new drug targeting LAG3.